Abstract: Methods and compositions are provided for the treatment of glaucoma and other optic neuropathies.

Abstract: The present invention relates to a method for selectively transducing retinal and optic nerve head (ONH) astrocytes using adeno-associated virus serotype 5 (AAV5) in combination with a modified glial fibrillary acidic protein promoter (gfaABC1D) for delivery of gene therapies (recombinant DNA, shRNA, Crispr/Cas9) to treat glaucoma or other optic neuropathies

Abstract: The present invention provides methods for the identification, isolation and/or enrichment of human corneal endothelial cells (HCECs). In some embodiments, the method comprises a positive selection process in which a cell population containing human corneal cells is contacted with a positive affinity reagent that selectively binds to HCECs relative to cells other than HCECs (e.g., corneal keratocytes, etc.) in the population and/or a negative selection process in which a cell population containing HCECs is contacted with a negative affinity reagent that selectively binds to cells other than HCECs in the population relative to HCECs. The present invention also provides reagents and kits for the identification, isolation and/or enrichment of HCECs as well as compositions that are enriched in HCECs.

Abstract: In certain aspects, the invention is directed to magnetic eye shields that comprise a magnet. When worn by a patient, the magnetic eye shields are configured to generate an intraocular magnetic field of sufficient magnitude and direction to move a magnetic therapeutic and/or diagnostic agent positioned inside the eye to target tissue within the eye. Other aspects of the invention pertain to kits which comprise such magnetic eye shields as well as one or more additional components, for example, one or more containers of a magnetic diagnostic and/or or therapeutic agent. Further aspects of the invention pertain to methods of treatment, which comprise intraocularly introducing a magnetic therapeutic and/or diagnostic agent into an eye of a patient and fitting a magnetic eye shield to the head of the patient, wherein the magnetic therapeutic and/or diagnostic agent may be introduced to the patient before or after fitting the magnetic eye shield to the head of the patient.

Abstract: The present invention provides methods for the identification, isolation and/or enrichment of human corneal endothelial cells (HCECs). In some embodiments, the method comprises a positive selection process in which a cell population containing human corneal cells is contacted with a positive affinity reagent that selectively binds to HCECs relative to cells other than HCECs (e.g., corneal keratocytes, etc.) in the population and/or a negative selection process in which a cell population containing HCECs is contacted with a negative affinity reagent that selectively binds to cells other than HCECs in the population relative to HCECs. The present invention also provides reagents and kits for the identification, isolation and/or enrichment of HCECs as well as compositions that are enriched in HCECs.

Abstract: Nervous system trauma and neurodegeneration including in optic neuropathies are treated by administration of an effective dose of a PDE4D3 displacing agent to promote neurite extension, neuroprotection and recovery. In some embodiments the neurons are optic neurons, including without limitation retinal ganglion cells (RGCs). A cAMP signaling compartment restricted by mAKAP?-anchored PDE4D3 directly regulates neuronal phenotype, and can be molecularly manipulated with therapeutic effect.

Abstract: The present invention provides methods for the identification, isolation and/or enrichment of human corneal endothelial cells (HCECs). In some embodiments, the method comprises a positive selection process in which a cell population containing human corneal cells is contacted with a positive affinity reagent that selectively binds to HCECs relative to cells other than HCECs (e.g., corneal keratocytes, etc.) in the population and/or a negative selection process in which a cell population containing HCECs is contacted with a negative affinity reagent that selectively binds to cells other than HCECs in the population relative to HCECs. The present invention also provides reagents and kits for the identification, isolation and/or enrichment of HCECs as well as compositions that are enriched in HCECs.

Abstract: The present invention provides methods for the identification, isolation and/or enrichment of human corneal endothelial cells (HCECs). In some embodiments, the method comprises a positive selection process in which a cell population containing human corneal cells is contacted with a positive affinity reagent that selectively binds to HCECs relative to cells other than HCECs (e.g., corneal keratocytes, etc.) in the population and/or a negative selection process in which a cell population containing HCECs is contacted with a negative affinity reagent that selectively binds to cells other than HCECs in the population relative to HCECs. The present invention also provides reagents and kits for the identification, isolation and/or enrichment of HCECs as well as compositions that are enriched in HCECs.

Abstract: Normal or genetically modified cell(s) having magnetic nanoparticle(s) bound (affixed) to their surfaces and methods of delivery to target tissues, e.g. for treatment of disease and/or injury.

Abstract: In certain aspects, the present invention is directed to a device selected from (a) an operating microscope with an attached or attachable magnet and (b) a magnet that is configured for attachment to an operating microscope. In either case, the magnet is configured to allow a patient's tissue to be viewed through the operating microscope while at the same time permitting the creation of a magnetic field of sufficient magnitude and direction to move a magnetic therapeutic and/or diagnostic agent lying within the tissue to a preferred location in the tissue.

Abstract: In certain aspects, the invention is directed to magnetic eye shields that comprise a magnet. When worn by a patient, the magnetic eye shields are configured to generate an intraocular magnetic field of sufficient magnitude and direction to move a magnetic therapeutic and/or diagnostic agent positioned inside the eye to target tissue within the eye. Other aspects of the invention pertain to kits which comprise such magnetic eye shields as well as one or more additional components, for example, one or more containers of a magnetic diagnostic and/or or therapeutic agent. Further aspects of the invention pertain to methods of treatment, which comprise intraocularly introducing a magnetic therapeutic and/or diagnostic agent into an eye of a patient and fitting a magnetic eye shield to the head of the patient, wherein the magnetic therapeutic and/or diagnostic agent may be introduced to the patient before or after fitting the magnetic eye shield to the head of the patient.

Abstract: Normal or genetically modified cell(s) having magnetic nanoparticle(s) bound (affixed) to their surfaces and methods of delivery to target tissues, e.g. for treatment of disease and/or injury.

Abstract: In certain aspects, the invention is directed to magnetic eye shields that comprise a magnet. When worn by a patient, the magnetic eye shields are configured to generate an intraocular magnetic field of sufficient magnitude and direction to move a magnetic therapeutic and/or diagnostic agent positioned inside the eye to target tissue within the eye. Other aspects of the invention pertain to kits which comprise such magnetic eye shields as well as one or more additional components, for example, one or more containers of a magnetic diagnostic and/or or therapeutic agent. Further aspects of the invention pertain to methods of treatment, which comprise intraocularly introducing a magnetic therapeutic and/or diagnostic agent into an eye of a patient and fitting a magnetic eye shield to the head of the patient, wherein the magnetic therapeutic and/or diagnostic agent may be introduced to the patient before or after fitting the magnetic eye shield to the head of the patient.

Abstract: A method of inserting and securing a corneal implant in engaging and fluid-flow limiting relation to the posterior cornea, such as to treat edema. The method includes securing a corneal implant in fluid flow limiting relation to the posterior cornea through an incision in the eye and securing it in place by a variety of steps such as corneal insertion or laser bonding, and preferably by inserting a removable corneal implant including a central region and a plurality of retention member(s) disposed on the periphery thereof into the eye so as to releasably and removably engage a portion of the eye and thereby retain the corneal implant in abutting and engaging relation with the posterior cornea. The retention members of the corneal implant may also comprise haptic leg(s) extending from the central region.

Abstract: Normal or genetically modified cell(s) having magnetic nanoparticle(s) bound (affixed) to their surfaces and methods of delivery to target tissues, e.g. for treatment of disease and/or injury.

Abstract: Provided are methods and compositions for treating an ocular disease associated with increased intraocular pressure using a therapeutically effective amount of receptor associated protein (RAP), a derivative of RAP, a variant of RAP, or a fragment of RAP. Also provided are methods and compositions for reducing intraocular pressure.

Abstract: A method of inserting and securing a corneal implant in engaging and fluid-flow limiting relation to the posterior cornea, such as to treat edema. The method includes securing a corneal implant in fluid flow limiting relation to the posterior cornea through an incision in the eye and securing it in place by a variety of steps such as corneal insertion or laser bonding, and preferably by inserting a removable corneal implant including a central region and a plurality of retention member(s) disposed on the periphery thereof into the eye so as to releaseably and removably engage a portion of the eye and thereby retain the corneal implant in abutting and engaging relation with the posterior cornea. The retention members of the corneal implant may also comprise haptic leg(s) extending from the central region.

Abstract: Normal or genetically modified cell(s) having magnetic nanoparticle(s) bound (affixed) to their surfaces and methods of delivery to target tissues, e.g. For treatment of disease and/or injury.

Abstract: A method of inserting and securing a corneal implant in engaging and fluid-flow limiting relation to the posterior cornea, such as to treat edema. The method includes securing a corneal implant in fluid flow limiting relation to the posterior cornea through an incision in the eye and securing it in place by a variety of steps such as corneal insertion or laser bonding, and preferably by inserting a removable corneal implant including a central region and a plurality of retention member(s) disposed on the periphery thereof into the eye so as to releaseably and removably engage a portion of the eye and thereby retain the corneal implant in abutting and engaging relation with the posterior cornea. The retention members of the corneal implant may also comprise haptic leg(s) extending from the central region.

Abstract: A method of inserting and securing a corneal implant in engaging and fluid-flow limiting relation to the posterior cornea, such as to treat edema. The method includes securing a corneal implant in fluid flow limiting relation to the posterior cornea through an incision in the eye and securing it in place by a variety of steps such as corneal insertion or laser bonding, and preferably by inserting a removable corneal implant including a central region and a plurality of retention member(s) disposed on the periphery thereof into the eye so as to releaseably and removably engage a portion of the eye and thereby retain the corneal implant in abutting and engaging relation with the posterior cornea. The retention members of the corneal implant may also comprise haptic leg(s) extending from the central region.